| GTO ID | GTC2710 |
| Trial ID | NCT04919473 |
| Disease | Retinitis Pigmentosa | Retinal Disease | Retinal Degeneration |
| Altered gene | MCO |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | vMCO-I|AAV2-MCO |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Phase I/IIa Open Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa |
| Year | 2021 |
| Country | Italy |
| Company sponsor | Nanoscope Therapeutics Inc. |
| Other ID(s) | NSCT/CT/18/01 |
| Vector information | |||||||||
|
|||||||||
| Cohort1: dose level 1 | |||||||||
|
|||||||||
| Cohort2: dose level 2 | |||||||||
|
|||||||||